^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YTS105

    i
    Other names: YTS105, S105, MSLN STAR-T Cells
    Associations

    News

    Trials
    Company:
    BriSTAR Immunotech, Peking University
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Peking University
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSLN (Mesothelin)
    |
    ALK positive • EGFR positive • EGFR negative • MSLN positive
    |
    YTS105